What can actually be done about it
Including one thing that works before symptoms start, and a drug most people have not heard of.
Prevention, before anything has gone wrong. This is the piece most often missed. The US Preventive Services Task Force recommends that clinicians provide or refer pregnant and postpartum people at increased risk of perinatal depression to counseling interventions. It found convincing evidence that counseling, specifically cognitive behavioral therapy and interpersonal therapy, prevents perinatal depression, with moderate certainty of a moderate net benefit. Increased risk includes a history of depression, current symptoms, or certain social circumstances such as low income or single parenthood.
Note what the Task Force judged inadequate: health system interventions, physical activity, education, the specific drugs studied for prevention (nortriptyline and sertraline), and omega-3 supplements. The evidence is for talking therapy, offered before you are ill.
This is the rarest thing in the whole postpartum literature: an intervention with good evidence that has to be started before the problem appears.
Antidepressants. Most are compatible with breastfeeding, and the amount that reaches the baby is generally low. This guide does not print transfer percentages for individual drugs, because it could not verify them against a primary source. The reliable reference is the NIH LactMed database, and it is free. What should not happen is a woman being told to choose between treating her depression and feeding her baby, when in most cases that is a false choice.
Two drugs developed specifically for postpartum depression.
| Zuranolone | Brexanolone | |
|---|---|---|
| How it is given | Capsule, 50 mg once daily in the evening with fatty food, for 14 days | A single 60-hour intravenous infusion |
| Trial result | Depression score fell 15.6 points against 11.6 on placebo, a difference of 4.0 (95% CI 1.7 to 6.3), in 196 women with severe symptoms | Two randomized trials, 246 women in total |
| How fast | Separation from placebo by day 3 | Measured at 60 hours |
| Common side effects | Sleepiness, dizziness, sedation | Not verified for this guide. Ask what monitoring the infusion requires and why |
ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects. Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after administration. Patients may not be able to assess their own driving competence or the degree of impairment caused by ZURZUVAE.
And the randomized trials followed women to day 45. What happens after day 45 has not been established in those trials. That is a real limitation for a fourteen-day course, and it is not the same as saying the benefit wears off. It means nobody measured.
None of this replaces the ordinary things: sleep that is protected by someone else, practical help, and being asked how you are by a person who waits for the answer. But when those are not enough, there is more available than most women are told about.